The Company’s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect:


	March 31,
	2026	2025
Common stock options granted and outstanding	4,755,322	3,716,173
Restricted stock units granted and outstanding	197,778	29,740
Common stock warrants outstanding	163,769	164,676
ESPP shares pending purchase	18,343	6,194
Total	5,135,212	3,916,783